- Home
- EVAX vs GRFX Comparison
EVAX vs GRFX Comparison
Compare EVAX & GRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- GRFX
- Stock Information
- Founded
- EVAX 2008
- GRFX 1981
- Country
- EVAX Denmark
- GRFX Hong Kong
- Employees
- EVAX N/A
- GRFX N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- GRFX
- Sector
- EVAX Health Care
- GRFX
- Exchange
- EVAX Nasdaq
- GRFX Nasdaq
- Market Cap
- EVAX 14.3M
- GRFX 12.3M
- IPO Year
- EVAX 2021
- GRFX N/A
- Fundamental
- Price
- EVAX $1.37
- GRFX $0.20
- Analyst Decision
- EVAX Strong Buy
- GRFX
- Analyst Count
- EVAX 2
- GRFX 0
- Target Price
- EVAX $11.00
- GRFX N/A
- AVG Volume (30 Days)
- EVAX 40.9K
- GRFX 74.5K
- Earning Date
- EVAX 10-31-2024
- GRFX 01-01-0001
- Dividend Yield
- EVAX N/A
- GRFX N/A
- EPS Growth
- EVAX N/A
- GRFX N/A
- EPS
- EVAX N/A
- GRFX N/A
- Revenue
- EVAX $3,295,000.00
- GRFX $30,019,108.00
- Revenue This Year
- EVAX $4,845.21
- GRFX N/A
- Revenue Next Year
- EVAX $30.30
- GRFX N/A
- P/E Ratio
- EVAX N/A
- GRFX N/A
- Revenue Growth
- EVAX N/A
- GRFX N/A
- 52 Week Low
- EVAX $1.28
- GRFX $0.14
- 52 Week High
- EVAX $13.61
- GRFX $1.22
- Technical
- Relative Strength Index (RSI)
- EVAX 22.79
- GRFX 41.32
- Support Level
- EVAX $1.28
- GRFX $0.19
- Resistance Level
- EVAX $1.80
- GRFX $0.24
- Average True Range (ATR)
- EVAX 0.27
- GRFX 0.03
- MACD
- EVAX -0.10
- GRFX -0.00
- Stochastic Oscillator
- EVAX 6.08
- GRFX 24.43
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About GRFX Graphex Group Limited each representing 20
Graphex Group Ltd is engaged in the sale of graphene products. It operates in three segments namely, the Graphene Products Segment includes Processing and sale of graphite and graphene-related products; the Landscape Architecture Design Segment includes Providing landscape architecture design; and the catering business focuses on the operation of restaurants. The company derives the majority of its revenue from the sale of graphene products segment.